UK markets closed

180 Life Sciences Corp. (ATNF)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
2.0000+0.0300 (+1.52%)
At close: 04:00PM EDT
2.0000 0.00 (0.00%)
After hours: 07:34PM EDT

180 Life Sciences Corp.

Building 4
Suite 200 3000 El Camino Real
Palo Alto, CA 94306
United States
650 507 0669
https://180lifesciences.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees4

Key executives

NameTitlePayExercisedYear born
Dr. Lawrence Steinman BA, M.D., Ph.D.Co-Founder & Executive Chairman168.75kN/A1948
Dr. James N. Woody M.D., Ph.D.CEO & Director617.77kN/A1942
Mr. Ozan Pamir C.F.A.CFO & Secretary410.24kN/A1992
Dr. Jonathan B. Rothbard Ph.D.Chief Scientific Officer260.34kN/A1953
Prof. Jagdeep NanchahalCo-Founder & Chairman of Clinical Advisory BoardN/AN/AN/A
Mr. Jason AssadDirector of IRN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Palo Alto, California.

Corporate governance

180 Life Sciences Corp.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.